SCHEMBL6314656

SCHEMBL6314656

Cn1c(=O)c2nc(C=C[N+](=O)[O-])cnc2n(C)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.45
GAA P10253 3/20 0.45
RXFP1 Q9HBX9 1/20 0.45
HSD17B10 Q99714 3/20 0.42
LMNA P02545 2/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
ALDH1A1 P00352 5/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 3/20 0.40
HTT P42858 2/20 0.40
JAK2 O60674 1/20 0.40
PAX8 Q06710 1/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
GLA P06280 1/20 0.38
ADORA2A P29274 2/20 0.36
ADORA2B P29275 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314712 0.79 ALDH1A1 (0.49) KDM4EGAARXFP1HSD17B10LMNA
SCHEMBL5440337 0.76 KDM4E (0.53) KDM4EGAAHSD17B10LMNACASP1
SCHEMBL6315474 0.76 KDM4E (0.53) KDM4EGAAHSD17B10LMNACASP1
SCHEMBL6316300 0.75 KDM4E (0.44) KDM4EGAARXFP1HSD17B10LMNA
SCHEMBL6316569 0.74 TNF (0.47) KDM4EGAARXFP1HSD17B10LMNA
SCHEMBL6316381 0.73 KMT2A (0.46) KDM4EGAARXFP1HSD17B10LMNA
SCHEMBL5442970 0.72 MAOB (0.49) KDM4EGAARXFP1HSD17B10LMNA
SCHEMBL5445042 0.70 KDM4E (0.56) KDM4EGAARXFP1HSD17B10LMNA
SCHEMBL5434551 0.69 MAPT (0.41) KDM4EGAAHSD17B10LMNACASP1
SCHEMBL6315801 0.69 ALDH1A1 (0.51) KDM4EGAARXFP1HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US claimed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US claimed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP claimed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO claimed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP disclosed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1278/4885GAA 3226/4885RXFP1 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.